Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MDGL Madrigal Pharmaceuticals

Market Closed 05-10 16:00:00 EDT

205.25

-1.67

-0.81%

盘后205.25

+0.000.00%

16:30 EDT

High208.74	Low203.86	Vol234.07K
Open206.40	D1 Closing206.92	Amplitude2.36%
Mkt Cap4.37B	Tradable Cap2.77B	Total Shares21.31M
T/O48.04M	T/O Rate1.74%	Tradable Shares13.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals","latestPrice":205.25,"timestamp":1715371200000,"preClose":206.92,"halted":0,"volume":234068,"hourTrading":{"tag":"盘后","latestPrice":205.25,"preClose":205.25,"latestTime":"16:30 EDT","volume":4047,"amount":830645.7,"timestamp":1715373013357},"delay":0,"floatShares":13479170,"shares":21311526,"eps":-23.212076,"marketStatus":"Market Closed","change":-1.67,"latestTime":"05-10 16:00:00 EDT","open":206.4,"high":208.74,"low":203.86,"amount":48040875.2239,"amplitude":0.023584,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-23.212076,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1715587200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":206.92,"preHourTrading":{"tag":"盘前","latestPrice":202.89,"preClose":206.92,"latestTime":"08:57 EDT","volume":93,"amount":19021.96983,"timestamp":1715345864073},"postHourTrading":{"tag":"盘后","latestPrice":205.25,"preClose":205.25,"latestTime":"16:30 EDT","volume":4047,"amount":830645.7,"timestamp":1715373013357},"volumeRatio":0.4341110690707661},"requestUrl":"/m/hq/s/MDGL/wiki","defaultTab":"wiki","newsList":[{"id":"2434304353","title":"Analysts Conflicted on These Healthcare Names: Madrigal Pharmaceuticals (MDGL) and Warby Parker (WRBY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434304353","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434304353?lang=en_us&edition=fundamental","pubTime":"2024-05-10 01:20","pubTimestamp":1715275207,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Madrigal Pharmaceuticals (MDGL – Research Report) and Warby Parke...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-madrigal-pharmaceuticals-mdgl-and-warby-parker-wrby?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-madrigal-pharmaceuticals-mdgl-and-warby-parker-wrby?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434774805","title":"Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2434774805","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2434774805?lang=en_us&edition=fundamental","pubTime":"2024-05-09 01:23","pubTimestamp":1715188981,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-7.38 EPS, expectations were $-6.06. MDGL isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter .Operator: Good day, and thank you for standing by. Welcome to Madrigal Pharmaceuticals First Quarter 2024 Earnings Conference Call. [Operator Instructions]. As a reminder, today's conference is being recorded. I would now like to introduce Ms. Tina Ventura, Chief Investor Relations Officer. Please go ahead.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jtCaEnP6EKRgpGDacKXjjw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1cfa181625bc50a71fdc5dd9e1953061","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jtCaEnP6EKRgpGDacKXjjw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1cfa181625bc50a71fdc5dd9e1953061"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/madrigal-pharmaceuticals-inc-nasdaq-mdgl-172301955.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433748386","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Esperion (ESPR) and Madrigal Pharmaceuticals (MDGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2433748386","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2433748386?lang=en_us&edition=fundamental","pubTime":"2024-05-08 17:32","pubTimestamp":1715160771,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Inozyme Pharma (INZY – Research Report), Esperion (ESPR – Researc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-inozyme-pharma-inzy-esperion-espr-and-madrigal-pharmaceuticals-mdgl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-inozyme-pharma-inzy-esperion-espr-and-madrigal-pharmaceuticals-mdgl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2433468716","title":"Madrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2433468716","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2433468716?lang=en_us&edition=fundamental","pubTime":"2024-05-08 15:02","pubTimestamp":1715151760,"startTime":"0","endTime":"0","summary":"Net Cash Balance: As of March 31st, 2024, stood at $1.1 billion.R&D Expenses: For Q1 2024 were $71 million, up from $62 million in Q1 2023.SG&A Expenses: Increased to $81 million in Q1 2024 from $16 million in Q1 2023.Public Offering: Raised $690 million in gross proceeds.Revenue: No revenue recorded for Q1 2024 as product shipments began in April.GuruFocus has detected 4 Warning Signs with MDGL.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Madrigal Pharmaceuticals Inc  achieved US FDA approval for its NASH treatment, marking a significant milestone in its commercial strategy.The company successfully launched its patient support program and began shipping its NASH treatment product to specialty pharmacy networks, ensuring availability for patients.The company's NASH treatment has been added to medical compendia and electronic medical records systems, facilitating easier prescription processes for healthcare providers.Madrigal Pharma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/madrigal-pharmaceuticals-inc-mdgl-q1-070240703.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433763472","title":"Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Promising Launch of First Approved NASH Treatment and Strong Market Positioning","url":"https://stock-news.laohu8.com/highlight/detail?id=2433763472","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2433763472?lang=en_us&edition=fundamental","pubTime":"2024-05-08 09:15","pubTimestamp":1715130919,"startTime":"0","endTime":"0","summary":"Analyst David Lebovitz of Citi maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), reducing the price target to $382.00. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-madrigal-pharmaceuticals-amid-promising-launch-of-first-approved-nash-treatment-and-strong-market-positioning?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-madrigal-pharmaceuticals-amid-promising-launch-of-first-approved-nash-treatment-and-strong-market-positioning?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2433557467","title":"BRIEF-Madrigal Pharmaceuticals Files For Common Stock Offering Of Up To $300 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2433557467","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2433557467?lang=en_us&edition=fundamental","pubTime":"2024-05-08 06:08","pubTimestamp":1715119687,"startTime":"0","endTime":"0","summary":"May 7 (Reuters) - Madrigal Pharmaceuticals Inc   :   * MADRIGAL PHARMACEUTICALS INC FILES FOR COMMON STOCK OFFERING OF UP TO $300 MILLION - SEC FILINGSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433758933","title":"Madrigal Pharmaceuticals’ Strategic Stock Sales Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2433758933","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2433758933?lang=en_us&edition=fundamental","pubTime":"2024-05-08 04:52","pubTimestamp":1715115175,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals Inc (MDGL) has shared an update. Madrigal Pharmaceuticals has entered into a Sales Agreement with TD Securities, with the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/madrigal-pharmaceuticals-strategic-stock-sales-agreements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/madrigal-pharmaceuticals-strategic-stock-sales-agreements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2433373069","title":"Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Rezdiffra Launch and Solid Financials","url":"https://stock-news.laohu8.com/highlight/detail?id=2433373069","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2433373069?lang=en_us&edition=fundamental","pubTime":"2024-05-08 04:45","pubTimestamp":1715114719,"startTime":"0","endTime":"0","summary":"Jonathan Wolleben, an analyst from JMP Securities, reiterated the Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report). The associated p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-madrigal-pharmaceuticals-amid-strong-rezdiffra-launch-and-solid-financials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-madrigal-pharmaceuticals-amid-strong-rezdiffra-launch-and-solid-financials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2433785143","title":"BUZZ-Madrigal falls on 'light' details on recently approved NASH drug launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2433785143","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2433785143?lang=en_us&edition=fundamental","pubTime":"2024-05-07 22:17","pubTimestamp":1715091431,"startTime":"0","endTime":"0","summary":"** Shares of Madrigal Pharmaceuticals    down 7% at $219 in early trading        ** MDGL says shipped its recently approved drug Rezdiffra  in April, no revenue was booked in Q1 for the treatment         ** In March, MDGL's oral drug became the first approved treatment for a fatty liver disease known as non-alcoholic steatohepatitis       ** Co says first patients received Rezdiffra in April, does not disclose number of patients   ** B.Riley Securities analyst Mayank Mamtani said color from the company about Rezdiffra's launch \"was pretty light\"   ** While there were no revenue expectations for Q1 for Rezdiffra, investors were looking for \"some more color about how the launch is going in terms of specifically patient numbers or new script volume,\" said Mamtani   ** Co's operating expenses nearly double to $152.04 mln for Q1, due to timing of manufacturing and launch-related costs related to Rezdiffra    ** As of last close, MDGL up ~2% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433882477","title":"Madrigal Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2433882477","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2433882477?lang=en_us&edition=fundamental","pubTime":"2024-05-07 21:53","pubTimestamp":1715089990,"startTime":"0","endTime":"0","summary":"* Madrigal Pharmaceuticals Inc    reported a quarterly adjusted loss of $7.38 per share for the quarter ended in March, lower than the same quarter last year, when the company reported EPS of $-4.23. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433720975","title":"Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2433720975","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2433720975?lang=en_us&edition=fundamental","pubTime":"2024-05-07 20:34","pubTimestamp":1715085283,"startTime":"0","endTime":"0","summary":"Revenue: Reported as $0 for the first quarter of 2024, meeting the analyst estimate of $0.00 million.Net Loss: Reported at $147.54 million for the first quarter, exceeding the estimated net loss of $124.42 million.Earnings Per Share : Reported a loss of $7.38 per share, below the estimated loss of $6.29 per share.Research and Development Expenses: Increased to $71.24 million from $62.15 million in the same quarter the previous year.Total Operating Expenses: More than doubled to $152.04 million from $78.34 million in the first quarter of the previous year.Cash Position: Strengthened significantly with cash, cash equivalents, and marketable securities totaling $1.06 billion, up from $634.13 million at the end of the previous quarter.Madrigal's balance sheet remains robust with over $1.05 billion in cash, cash equivalents, and marketable securities, an increase from $634.13 million at the end of 2023. This financial stability is crucial as the company scales up its operations and invests ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/madrigal-pharmaceuticals-reports-mixed-q1-123443139.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433527427","title":"Madrigal Pharmaceuticals Q1 2024 GAAP EPS $(7.38) Misses $(6.17) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2433527427","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2433527427?lang=en_us&edition=fundamental","pubTime":"2024-05-07 19:21","pubTimestamp":1715080901,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(7.38) per share which missed the analyst consensus estimate of $(6.17) by 19.61 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38665095/madrigal-pharmaceuticals-q1-2024-gaap-eps-7-38-misses-6-17-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2433608279","title":"BRIEF-Madrigal Pharmaceuticals Q1 EPS USD -7.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2433608279","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2433608279?lang=en_us&edition=fundamental","pubTime":"2024-05-07 19:00","pubTimestamp":1715079647,"startTime":"0","endTime":"0","summary":"May 07 (Reuters) - Madrigal Pharmaceuticals Q1 net income USD -147.541 million. * Q1 operating income USD -152.037 million * Q1 operating expenses USD 152.037 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432090988","title":"Madrigal Pharmaceuticals Inc    expected to post a loss of $6.28 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2432090988","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432090988?lang=en_us&edition=fundamental","pubTime":"2024-05-03 22:34","pubTimestamp":1714746889,"startTime":"0","endTime":"0","summary":"* Madrigal Pharmaceuticals Inc     is expected to show no change in quarterly revenue when it reports  results on May 7 for the period ending March 31 2024   *    * LSEG's mean analyst estimate for Ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432808955","title":"Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label","url":"https://stock-news.laohu8.com/highlight/detail?id=2432808955","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432808955?lang=en_us&edition=fundamental","pubTime":"2024-05-01 04:30","pubTimestamp":1714509023,"startTime":"0","endTime":"0","summary":"MDGL has launched Rezdiffra, the first drug approved for nonalcoholic steatohepatitis (NASH).Rezdiffra faces competition from potential off-label use of GLP-1RA drugs like semaglutide and tirzepatide,","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1699116086/image_1699116086.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1699116086/image_1699116086.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4687687-madrigal-rezdiffra-launch-gets-underway-the-only-competition-is-off-label","is_publish_highlight":false,"gpt_icon":0},{"id":"2430363788","title":"Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2430363788","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430363788?lang=en_us&edition=fundamental","pubTime":"2024-04-27 00:23","pubTimestamp":1714148632,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences is a clinical-stage biopharmaceutical company researching a cure for metabolic dysfunction-related diseases by inhibiting fatty acid synthase.Revenue generated so far comes from li","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1360244592/image_1360244592.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1360244592/image_1360244592.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4686709-sagimet-biosciences-denifanstat-phase-3-a-promising-opportunity","is_publish_highlight":false,"gpt_icon":0},{"id":"2430449373","title":"Madrigal Statement on the Passing of Dr. Stephen Harrison","url":"https://stock-news.laohu8.com/highlight/detail?id=2430449373","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2430449373?lang=en_us&edition=fundamental","pubTime":"2024-04-25 04:00","pubTimestamp":1713988800,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., April 24, 2024  -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison.We offer our deepest condolences to Stephen’s family for their loss.Stephen was a colleague and friend to so many of us at Madrigal. He worked tirelessly to improve the lives of people with nonalcoholic steatohepatitis , and his contributions to the field will touch countless families across the globe for decades to come. So many of the recent innovations and achievements we’ve seen in NASH research stemmed from his constant collaboration with partners in academia, industry, the regulatory sciences, and the patient community.Stephen was much more than a brilliant investigator and physician; he was a true leader who inspired all of us with his commitment to patients. We’ll remember his sense of humor, his courtesy, and his boundless energy and optimism.The field of hepatology has lost a true giant.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7N3MAzczZuGCZhLcgXi2IQ--~B/aD03Nzt3PTM2MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4569c96927163aa87c649d3fe2a4b04d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7N3MAzczZuGCZhLcgXi2IQ--~B/aD03Nzt3PTM2MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4569c96927163aa87c649d3fe2a4b04d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/madrigal-statement-passing-dr-stephen-200000638.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430469650","title":"Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage","url":"https://stock-news.laohu8.com/highlight/detail?id=2430469650","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430469650?lang=en_us&edition=fundamental","pubTime":"2024-04-25 01:02","pubTimestamp":1713978150,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH.The NASH market is projected to reach $50 billion by 2035, maki","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1483000268/image_1483000268.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1483000268/image_1483000268.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4685718-madrigal-2-challenges-to-overcome-to-maintain-nash-first-mover-advantage","is_publish_highlight":false,"gpt_icon":0},{"id":"2429110059","title":"3 Potential Biopharma Buyout Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2429110059","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2429110059?lang=en_us&edition=fundamental","pubTime":"2024-04-24 01:12","pubTimestamp":1713892368,"startTime":"0","endTime":"0","summary":"The recent lack of M&A activity and rising interest rates have helped trigger an approximate 20% decline in small-cap biotech equities.Drug blockbusters facing key patent expirations and Big Pharma's ","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1479134763/image_1479134763.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1479134763/image_1479134763.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4685355-3-potential-biopharma-buyout-targets","is_publish_highlight":false,"gpt_icon":0},{"id":"2429966581","title":"Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2429966581","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2429966581?lang=en_us&edition=fundamental","pubTime":"2024-04-23 12:00","pubTimestamp":1713844800,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., April  23, 2024  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results onTuesday, May 7, 20","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/23/2867611/0/en/Madrigal-Pharmaceuticals-to-Release-First-Quarter-2024-Financial-Results-and-Host-Webcast-on-May-7-2024.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":-0.107},{"period":"1month","weight":-0.1611},{"period":"3month","weight":0.0809},{"period":"6month","weight":0.4783},{"period":"1year","weight":-0.2876},{"period":"ytd","weight":-0.1129}],"compareEarnings":[{"period":"1week","weight":0.0187},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0392},{"period":"6month","weight":0.1821},{"period":"1year","weight":0.2638},{"period":"ytd","weight":0.0958}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.032263},{"month":2,"riseRate":0.75,"avgChangeRate":0.088162},{"month":3,"riseRate":0.25,"avgChangeRate":-0.038862},{"month":4,"riseRate":0.5,"avgChangeRate":0.008688},{"month":5,"riseRate":0.375,"avgChangeRate":0.149884},{"month":6,"riseRate":0.571429,"avgChangeRate":0.00101},{"month":7,"riseRate":0,"avgChangeRate":-0.103727},{"month":8,"riseRate":0.625,"avgChangeRate":0.081916},{"month":9,"riseRate":0.375,"avgChangeRate":0.16708},{"month":10,"riseRate":0.625,"avgChangeRate":0.051439},{"month":11,"riseRate":0.5,"avgChangeRate":0.037474},{"month":12,"riseRate":0.5,"avgChangeRate":0.475789}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Madrigal Pharmaceuticals,MDGL,Madrigal Pharmaceuticals股票,Madrigal Pharmaceuticals股票老虎,Madrigal Pharmaceuticals股票老虎国际,Madrigal Pharmaceuticals行情,Madrigal Pharmaceuticals股票行情,Madrigal Pharmaceuticals股价,Madrigal Pharmaceuticals股市,Madrigal Pharmaceuticals股票价格,Madrigal Pharmaceuticals股票交易,Madrigal Pharmaceuticals股票购买,Madrigal Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction